Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies

Journal of Clinical Oncology

Volumn 29, Issue 5, 2011, Pages 573-582

  Tefferi, Ayalew ^a   Vainchenker, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; AZD 1480; BUSULFAN; CYT 387; CYT 487; DANAZOL; FLUOXYMESTERONE; GIVINOSTAT; HYDROXYUREA; IKAROS TRANSCRIPTION FACTOR; INCB 018424; ISOCITRATE DEHYDROGENASE; ITF 387; JANUS KINASE INHIBITOR; LENALIDOMIDE; LESTAURTINIB; PANOBINOSTAT; PHOSPHORUS; PHOSPHORUS 32; PHOSPHOTRANSFERASE INHIBITOR; PIPOBROMAN; POMALIDOMIDE; PREDNISONE; SB 1518; TESTOSTERONE ENANTATE; TG 101348; THALIDOMIDE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VORINOSTAT;

ABDOMINAL DISCOMFORT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER SURVIVAL; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG TOLERABILITY; ERYTHROCYTOSIS; EXERCISE TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LEUKOCYTOSIS; LIFE EXPECTANCY; LOW DRUG DOSE; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NIGHT SWEAT; PATHOGENESIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SATIETY; SICKLE CELL ANEMIA; SIDE EFFECT; SPLEEN; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VEIN THROMBOSIS; VIRUS MUTATION; WEIGHT GAIN;

HUMANS; JANUS KINASE 2; MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 79952075257     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.8711     Document Type: Review

References (103)

1. Tefferi A: The history of myeloproliferative disorders: Before and after Dameshek. Leukemia 22: 3-13, 2008
2. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 6: 372-375, 1951
3. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114: 937-951, 2009
4. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24: 1128-1138, 2010
5. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148, 2005 (Pubitemid 40663494)
6. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790, 2005 (Pubitemid 40570926)
7. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005 (Pubitemid 40544655)
8. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005 (Pubitemid 40386783)
9. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468, 2007 (Pubitemid 46193073)
10. Pikman Y, Lee BH, Mercher T, et al: MPLW515L Is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270, 2006
11. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 108: 3472-3476, 2006
12. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301, 2009
13. Carbuccia N, Murati A, Trouplin V, et al: Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183-2186, 2009
14. Green A, Beer P: Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362: 369-370, 2010
15. Abdel-Wahab O, Manshouri T, Patel J, et al: Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70: 447-452, 2010
16. Pardanani A, Lasho T, Finke C, et al: IDH1 and IDH2 mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 24:1146-1151, 2010
17. Grand FH, Hidalgo-Curtis CE, Ernst T, et al: Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182-6192, 2009
18. Jager R, Gisslinger H, Berg T, et al: Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24:1290-1298, 2010
19. Oh ST, Simonds EF, Jones C, et al: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988-992, 2010
20. Ernst T, Chase AJ, Score J, et al: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726, 2010
21. Tiedt R, Hao-Shen H, Sobas MA, et al: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940, 2008
22. Scott LM, Scott MA, Campbell PJ, et al: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108:2435-2437, 2006 (Pubitemid 44497530)
23. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 22: 1299-1307, 2008
24. Passamonti F, Rumi E, Pietra D, et al: A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24: 1574-1579, 2010
25. Tefferi A, Lasho TL, Huang J, et al: Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:756-761, 2008 (Pubitemid 351559282)
26. Guglielmelli P, Barosi G, Specchia G, et al: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114: 1477-1483, 2009
27. Pardanani A, Lasho TL, Finke C, et al: Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21:1960-1963, 2007
28. Pietra D, Li S, Brisci A, et al: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111: 1686-1689, 2008 (Pubitemid 351213460)
29. Passamonti F, Schnittger S, Girodon F, et al: Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations: A European Multicenter Study. Blood 114: 3904, 2009
30. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112: 844-847, 2009
31. Beer PA, Campbell PJ, Scott LM, et al: MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 112: 141-149, 2008
32. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al: Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137: 244-247, 2007 (Pubitemid 46537640)
33. Tefferi A, Pardanani A, Lim KH, et al: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23: 905-911, 2009
34. Schaub FX, Looser R, Li S, et al: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115:2003-2007, 2010
35. Gelsi-Boyer V, Trouplin V, Adelaide J, et al: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145: 788-800, 2009
36. Carbuccia N, Trouplin V, Gelsi-Boyer V, et al: Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 24:469-473, 2010
37. Pardanani A, Patnaik MM, Lasho TL, et al: Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 24:1370-1372, 2010
38. Tefferi A, Lasho TL, Abdel-Wahab O, et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:1302-1309, 2010
39. Loh ML, Sakai DS, Flotho C, et al: Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114: 1859-1863, 2009
40. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453: 110-114, 2008 (Pubitemid 351630327)
41. Gery S, Cao Q, Gueller S, et al: Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 85: 957-965, 2009
42. Pardanani A, Lasho T, Finke C, et al: LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24:1713-1718, 2010
43. Lasho TL, Pardanani A, Tefferi A: LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 363: 1189-1190, 2010
44. Tefferi A, Thiele J, Orazi A, et al: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110: 1092-1097, 2007 (Pubitemid 47281402)
45. Tefferi A, Sirhan S, Lasho TL, et al: Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131: 166-171, 2005 (Pubitemid 43899681)
46. James C, Delhommeau F, Marzac C, et al: Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20: 350-353, 2006 (Pubitemid 43148676)
47. Mossuz P, Girodon F, Donnard M, et al: Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89:1194-1198, 2004
48. Tefferi A, Skoda R, Vardiman JW: Myeloproliferative neoplasms: Contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 6: 627-637, 2009
49. Kvasnicka HM, Thiele J: Classification of Ph-negative chronic myeloproliferative disorders-morphology as the yardstick of classification. Pathobiology 74: 63-71, 2007 (Pubitemid 46985278)
50. Barosi G, Mesa RA, Thiele J, et al: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22: 437-438, 2008 (Pubitemid 351250553)
51. Finazzi G, Barbui T: Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22: 1494-1502, 2008
52. Gangat N, Caramazza D, Vaidya R, et al: DIPSS Plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392-397, 2011
53. Passamonti F, Rumi E, Arcaini L, et al: Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica 93:1645-1651, 2008
54. Passamonti F, Rumi E, Pungolino E, et al: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117: 755-761, 2004 (Pubitemid 39482529)
55. Gangat N, Strand J, Li CY, et al: Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138: 354-358, 2007 (Pubitemid 47035399)
56. Di Nisio M, Barbui T, Di Gennaro L, et al: The haematocrit and platelet target in polycythemia vera. Br J Haematol 136: 249-259, 2007 (Pubitemid 46020752)
57. Budde U, Schaefer G, Mueller N, et al: Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 64: 981-985, 1984 (Pubitemid 15212036)
58. Gangat N, Wolanskyj AP, McClure RF, et al: Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 21: 270-276, 2007 (Pubitemid 46158119)
59. Tefferi A: Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasmsbiologically plausible but clinically uncertain. Am J Hematol 85: 93-94, 2009
60. Barbui T, Carobbio A, Rambaldi A, et al: Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood 114: 759-763, 2009
61. Tefferi A, Passamonti F: Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. Am J Hematol 84:629-630, 2009
62. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895-2901, 2009
63. Passamonti F, Cervantes F, Vannucchi AM, et al: A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115: 1703-1708, 2010
64. Caramazza D, Begna KH, Gangat N, et al: Refined cytogenetic risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia (in press)
65. Tefferi A, Lasho TL, Patnaik MM, et al: JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 24:105-109, 2010
66. Tam CS, Kantarjian H, Cortes J, et al: Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis. J Clin Oncol 27: 5587-5593, 2009
67. Huang J, Li CY, Mesa RA, et al: Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112: 2726-2732, 2008 (Pubitemid 351969217)
68. Dingli D, Schwager SM, Mesa RA, et al: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 106: 1985-1989, 2006
69. Passamonti F, Rumi E, Caramella M, et al: A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111: 3383-3387, 2008
70. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114-124, 2004 (Pubitemid 38056222)
71. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132-1136, 1995
72. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33-45, 2005 (Pubitemid 41007805)
73. Berk PD, Wasserman LR, Fruchtman SM, et al: Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group, in Wasserman LR, Berk PD, Berlin NI (eds): Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA, W.B. Saunders, 1995, pp 166-194
74. Alvarez-Larran A, Cervantes F, Pereira A, et al: Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116: 1205-1210, 2010
75. Budde U, Scharf RE, Franke P, et al: Elevated platelet count as a cause of abnormal von Wille-brand factor multimer distribution in plasma. Blood 82:1749-1757, 1993 (Pubitemid 23278765)
76. Quintas-Cardama A, Kantarjian H, Manshouri T, et al: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27: 5418-5424, 2009
77. Kiladjian JJ, Cassinat B, Chevret S, et al: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112: 3065-3072, 2008
78. Shvidel L, Sigler E, Haran M, et al: Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 21: 2071-2072, 2007 (Pubitemid 47299992)
79. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 44: 75-80, 1981
80. Finazzi G, Caruso V, Marchioli R, et al: Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 105:2664-2670, 2005
81. Najean Y, Rain JD: Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90: 3370-3377, 1997 (Pubitemid 27473405)
82. Gangat N, Wolanskyj AP, McClure RF, et al: Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 21: 270-276, 2007 (Pubitemid 46158119)
83. Voskaridou E, Christoulas D, Bilalis A, et al: The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 115: 2354-2363, 2010
84. Messinezy M, Pearson TC, Prochazka A, et al: Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: Retrospective study from one centre. Br J Haematol 61: 657-666, 1985 (Pubitemid 16231518)
85. Petrides E, Gotic M, Penka M, et al: Anahydret: A European Multicenter Prospective phase 3-study: Non-inferiority of anagrelide compared to hydroxyurea in newly who-diagnosed ET patients. Haematologica 94:440, 2009
86. Cervantes F, Mesa R, Barosi G: New and old treatment modalities in primary myelofibrosis. Cancer J 13:377-383, 2007
87. Huang J, Tefferi A: Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 83:154-155, 2009
88. Elliott MA, Mesa RA, Li CY, et al: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117: 288-296, 2002 (Pubitemid 34451143)
89. Thomas DA, Giles FJ, Albitar M, et al: Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106: 1974-1984, 2006
90. Mesa RA, Steensma DP, Pardanani A, et al: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101: 2534-2541, 2003 (Pubitemid 36857609)
91. Tefferi A, Cortes J, Verstovsek S, et al: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108: 1158-1164, 2006 (Pubitemid 44232010)
92. Mesa RA, Yao X, Cripe LD, et al: Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood 116:4436-4438, 2010
93. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al: Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27:4760-4766, 2009
94. Tefferi A, Lasho TL, Mesa RA, et al: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 21: 1827-1828, 2007
95. Mishchenko E, Tefferi A: Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 85: 192-199, 2010
96. Tefferi A, Verstovsek S, Barosi G, et al: Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27: 4563-4569, 2009
97. Begna KH, Mesa RA, Pardanani A, et al: A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia (in press)
98. Pardanani A, Gotlib JR, Jamieson C, et al: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (in press)
99. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
100. Verstovsek S, Passamonti F, Rambaldi A, et al: A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Blood 114:311, 2009
101. Pardanani A, George G, Lasho T, et al: A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: Significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood (in press)
102. Ballen KK, Shrestha S, Sobocinski KA, et al: Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16:358-367, 2010
103. Kroger N, Holler E, Kobbe G, et al: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114: 5264-5270, 2009